Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

1-2 years Efficacy phase (II)Confirmation phase (III)Post-Trial Drug Access Cost Reimbursement Partially Remote Standard Medicines InjectionAllergologyDermatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Adtralza

Adtralza is a medicine used to treat moderate-to-severe atopic dermatitis (eczema) in adults by helping reduce skin inflammation and itching.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Tralokinumab

Tralokinumab is a substance that targets an inflammatory protein to reduce severe eczema symptoms like itching and redness.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

UZ Leuven

Dermatology

Heverlee, Belgium

Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola

Dermatology

Jette, Belgium

Universitair Ziekenhuis Gent

Dermatology

Ledeberg, Belgium

Sponsor: Leo Pharma A/S

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.